MedPath

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Registration Number
NCT00061646
Lead Sponsor
Abbott
Brief Summary

The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
25
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Progression free survivalOne year
Secondary Outcome Measures
NameTimeMethod
Overall survivalOne year
Response rateOne year

Trial Locations

Locations (4)

Oncology-Hematology Group of South Florida

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

University of Chicago

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

The West Cancer Clinic

πŸ‡ΊπŸ‡Έ

Memphis, Tennessee, United States

University of Wisconsin

πŸ‡ΊπŸ‡Έ

Madison,, Wisconsin, United States

Oncology-Hematology Group of South Florida
πŸ‡ΊπŸ‡ΈMiami, Florida, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.